Status:
COMPLETED
Short-term Impact of Cyplexinol® on Self-reported Joint Pain
Lead Sponsor:
University of Memphis
Collaborating Sponsors:
ZyCal Bioceuticals
Conditions:
Joint Pain
Eligibility:
All Genders
30-65 years
Phase:
NA
Brief Summary
In this study, the impact of 900 mg Cyplexinol® taken daily on joint pain over a period of 15 days in comparison with a placebo will be determined using a cross-over double blind design with a 13 day ...
Detailed Description
Chronic inflammation can induce joint pain, which is a common problem among adult men and women. ZyCal Bioceuticals is a manufacturer of natural ingredients and finished nutritional supplements to sup...
Eligibility Criteria
Inclusion
- body mass index (BMI) between 18-29.9 kg/m2 (not obese)
- no consumption of alcohol-containing beverages within 48 hours of testing
- experiencing self-reported joint pain with a minimum pain rating of 3/10 for at least the past 30 days
- engaged in structured exercise 2 or more days per week for the past 6 months or longer
- a negative verbal pre-study drug screen (alcohol abuse, amphetamines, benzodiazepines, cocaine, opioids, phencyclidine, barbiturates, cotinine), no history of use of illicit drugs or other substances of abuse within 12 months of the screening visit
Exclusion
- pregnant
- tobacco user
- active infection or illness of any kind
- rheumatic or osteoarthritic diagnosis
- Using anti-inflammatory medicines, pain medications, or dietary supplements (or not willing to cease for one-month prior to participation and throughout study)
Key Trial Info
Start Date :
March 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 28 2022
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04764110
Start Date
March 17 2021
End Date
January 28 2022
Last Update
August 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Nutraceutical and Dietary Supplement Reseach
Memphis, Tennessee, United States, 38152